Get the Stockscreener App
14.85
1.50%
0.22
After Hours:
14.82
-0.03
-0.20%
Aardvark Therapeutics Inc stock is traded at $14.85, with a volume of 135.43K.
It is up +1.50% in the last 24 hours and up +72.88% over the past month.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
See More
Previous Close:
$14.63
Open:
$14.55
24h Volume:
135.43K
Relative Volume:
1.05
Market Cap:
$322.20M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-14.70%
1M Performance:
+72.88%
6M Performance:
+94.88%
1Y Performance:
+0.00%
1-Day Range:
$14.30
$15.11
1-Week Range:
$14.30
$17.94
52-Week Range:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Name
Aardvark Therapeutics Inc
Sector
Industry
Phone
(858) 225-7696
Address
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
14.85 | 352.73M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-25 | Initiated | Stifel | Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Initiated | BofA Securities | Buy |
| Mar-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-10-25 | Initiated | Morgan Stanley | Overweight |
| Mar-10-25 | Initiated | RBC Capital Mkts | Outperform |
View All
Aardvark Therapeutics Inc Stock (AARD) Latest News
Using Ichimoku Cloud for Aardvark Therapeutics Inc. technicalsMarket Volume Report & Accurate Intraday Trade Tips - newser.com
Will Aardvark Therapeutics Inc. stock outperform international peersEarnings Recap Report & Long-Term Safe Investment Ideas - newser.com
What’s the recovery path for long term holders of Aardvark Therapeutics Inc.Risk Management & Low Risk High Win Rate Picks - newser.com
Aardvark Therapeutics Inc. stock volume spike explainedTake Profit & Weekly Watchlist of Top Performers - newser.com
Is Aardvark Therapeutics Inc. stock ready for breakout2025 Key Highlights & Detailed Earnings Play Strategies - newser.com
What data driven models say about Aardvark Therapeutics Inc.’s future2025 Key Highlights & AI Forecast for Swing Trade Picks - newser.com
How risky is Aardvark Therapeutics Inc. stock nowMarket Volume Report & High Accuracy Trade Signal Alerts - newser.com
Using portfolio simulators with Aardvark Therapeutics Inc. includedJuly 2025 Closing Moves & Long-Term Capital Growth Strategies - newser.com
Aardvark Therapeutics Aligns with FDA on Trial Amendment - TipRanks
Aardvark Therapeutics (NASDAQ:AARD) Receives "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome - The Manila Times
Phase 3 HERO Expanded to Ages 10+ — Aardvark Aligns with FDA on ARD-101 Trial; Readout Q3 2026 - Stock Titan
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Aardvark Therapeutics Inc a good long term investmentPrice Action Analysis & Explosive Capital Growth - earlytimes.in
Insiders Of Aardvark Therapeutics Reap Rewards After Their Investment Jumps Another US$275k - 富途牛牛
Insiders Rewarded With US$275k Addition To Investment As Aardvark Therapeutics Stock Hits US$349m - simplywall.st
Using economic indicators to assess Aardvark Therapeutics Inc. potentialQuarterly Market Summary & Verified Momentum Watchlists - newser.com
What does recent volatility data suggest for Aardvark Therapeutics Inc.Trade Risk Report & Community Verified Swing Trade Signals - newser.com
Analyzing drawdowns of Aardvark Therapeutics Inc. with statistical tools2025 Short Interest & Real-Time Volume Spike Alerts - newser.com
H.C. Wainwright Maintains Aardvark Therapeutics(AARD.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Short Interest Update - Defense World
Aardvark Therapeutics Inc. stock trend forecastWeekly Risk Report & Accurate Technical Buy Alerts - newser.com
Should you wait for a breakout in Aardvark Therapeutics Inc.Short Setup & Real-Time Chart Breakout Alerts - newser.com
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Jones Trading - Defense World
Jones Trading Initiates Coverage of Aardvark Therapeutics (AARD) with Buy Recommendation - Nasdaq
This Coinbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
JonesTrading Initiates Aardvark Therapeutics(AARD.US) With Buy Rating, Announces Target Price $33 - 富途牛牛
Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics - TipRanks
Aardvark stock slides 11% following $94M IPO - MSN
Jones Trading initiates coverage on Aardvark Therapeutics stock with Buy rating - Investing.com Nigeria
Aardvark Therapeutics Inc Stock (AARD) Financials Data
There is no financial data for Aardvark Therapeutics Inc (AARD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):